Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CLDX
stocks logo

CLDX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
1.08M
-66.02%
-1.006
+41.7%
1.53M
+30.45%
-1.113
+37.45%
652.00K
-6.19%
-1.132
+33.14%
Estimates Revision
The market is revising Downward the revenue expectations for Celldex Therapeutics, Inc. (CLDX) for FY2025, with the revenue forecasts being adjusted by -21.83% over the past three months. During the same period, the stock price has changed by 29.43%.
Revenue Estimates for FY2025
Revise Downward
down Image
-21.83%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+4.84%
In Past 3 Month
Stock Price
Go Up
up Image
+29.43%
In Past 3 Month
Wall Street analysts forecast CLDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLDX is 54.67 USD with a low forecast of 21.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast CLDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLDX is 54.67 USD with a low forecast of 21.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
0 Hold
1 Sell
Strong Buy
Current: 29.600
sliders
Low
21.00
Averages
54.67
High
90.00
Current: 29.600
sliders
Low
21.00
Averages
54.67
High
90.00
Barclays
Underweight
downgrade
$25 -> $21
2025-11-11
Reason
Barclays
Price Target
$25 -> $21
2025-11-11
downgrade
Underweight
Reason
Barclays lowered the firm's price target on Celldex to $21 from $25 and keeps an Underweight rating on the shares following the Q3 report.
Mizuho
Outperform
initiated
$48
2025-10-20
Reason
Mizuho
Price Target
$48
2025-10-20
initiated
Outperform
Reason
Mizuho initiated coverage of Celldex with an Outperform rating and $48 price target. The firm sees barzolvolimab as positioned to play a significant role in mast-cell mediated diseases, namely chronic urticaria. Mizuho added that it believes barzolvolimab has potential to establish best-in-class efficacy among the increasingly competitive landscape, offering the deepest and most sustained clinical benefit.
Wells Fargo
Overweight
downgrade
$44 -> $38
2025-08-20
Reason
Wells Fargo
Price Target
$44 -> $38
2025-08-20
downgrade
Overweight
Reason
Wells Fargo lowered the firm's price target on Celldex to $38 from $44 and keeps an Overweight rating on the shares. Shares should be down 10%-15% on the failure in eosinophilic esophagitis, but he Street was not assigning much to this program, the analyst tells investors in a research note. The firm would buy shares on weakness.
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
$50 -> $42
2025-08-20
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$50 -> $42
2025-08-20
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Celldex to $42 from $50 and keeps a Buy rating on the shares. The company announced mixed topline results from its Phase 2 trial assessing barzolvolimab in eosinophilic esophagitis, the analyst tells investors in a research note. The firm removing eosinophilic esophagitis from its barzolvolimab projected indications.
Citi
Buy
downgrade
$56 -> $48
2025-08-20
Reason
Citi
Price Target
$56 -> $48
2025-08-20
downgrade
Buy
Reason
Citi lowered the firm's price target on Celldex to $48 from $56 and keeps a Buy rating on the shares. The company will not pursue barzolvolimab in eosinophilic esophagitis following the Phase 2 data, the analyst tells investors in a research note. Citi believes the shares were pricing in little to no value for this indication. Any selloff on the Phase 2 data will likely be temporary, the firm contends.
Canaccord
Buy
downgrade
$64 -> $62
2025-08-20
Reason
Canaccord
Price Target
$64 -> $62
2025-08-20
downgrade
Buy
Reason
Canaccord lowered the firm's price target on Celldex to $62 from $64 and keeps a Buy rating on the shares. The firm said its Phase II EoE study of barzolvolimab showed that the drug works, but just not for EoE. The company announced the discontinuation of the EoE program. Canaccord zeroed out the EoE program from their model, which leads to a $2 decrease in our 12-month PT. They believe these results do not have a read-through into the ongoing Phase III CSU study as well as the planned Phase III development in CIndU for barzolvolimab,
See All Ratings

Valuation Metrics

The current forward P/E ratio for Celldex Therapeutics Inc (CLDX.O) is -6.72, compared to its 5-year average forward P/E of -13.36. For a more detailed relative valuation and DCF analysis to assess Celldex Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-13.36
Current PE
-6.72
Overvalued PE
-7.21
Undervalued PE
-19.51

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.33
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.32
Undervalued EV/EBITDA
-5.99

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
568.50
Current PS
0.00
Overvalued PS
847.78
Undervalued PS
289.22
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

CLDX News & Events

Events Timeline

(ET)
2025-11-10
16:02:51
Celldex Announces Q3 Earnings Per Share of $1.01, Exceeding Consensus Estimate of 89 Cents
select
2025-11-10
08:28:33
Celldex names Lawver as Chief Commercial Officer
select
2025-11-06 (ET)
2025-11-06
08:33:43
Celldex Reveals Findings from Phase 2 Study of Barzolvolimab in ColdU, SD
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-01Businesswire
Cleveland Diagnostics' IsoPSA Receives FDA Approval, Enhancing Prostate Biopsy Decision-Making
  • FDA Approval Milestone: Cleveland Diagnostics' IsoPSA® in vitro diagnostic kit has received FDA approval through the Premarket Approval process, marking a significant advancement in early cancer detection and is expected to greatly enhance physician confidence in prostate biopsy decision-making.
  • Clinical Research Support: The FDA approval of IsoPSA is based on robust clinical evidence from a large-scale prospective study conducted at 14 sites across the U.S., addressing the diagnostic gap where over 1 million men undergo prostate biopsies annually, yet only 25% yield positive results for high-grade disease.
  • Cost Reduction in Healthcare: By providing more accurate risk assessments, IsoPSA helps reduce unnecessary invasive procedures and associated healthcare costs, which is anticipated to alleviate physical risks and emotional stress for patients, thereby improving the overall healthcare experience.
  • Market Access Expansion: Since its introduction as a Laboratory-Developed Test (LDT) in 2020, IsoPSA has gained coverage from Medicare and an increasing number of commercial payors, further driving its application in clinical practice and enhancing patient accessibility.
[object Object]
Preview
4.5
11-11Benzinga
Tech Stocks Surge, Palantir Soars 6% as Shutdown Resolution Approaches: Market Movers for Monday

  • Market Recovery: Wall Street saw a rebound on Monday, with the Nasdaq 100 rising nearly 1.5% and Palantir Technologies gaining 6.2%, as investors grew optimistic about a potential end to the government shutdown following Senate progress on a reopening bill.

  • Commodities and Cryptocurrencies: Gold and silver prices increased due to safe-haven demand amid rising government debt, while Bitcoin edged up 0.3% to reclaim the $105,000 mark, contrasting with a 1.5% drop in Ethereum.

  • Major Indices Performance: The S&P 500 gained 0.8%, the Russell 2000 rose 0.7%, and the Dow Jones Industrial Average added 0.1%, reflecting a positive day for major U.S. indices.

  • Earnings Movers: Notable stock movements included TreeHouse Foods surging 23.3% and Organon & Co. rising 11.9%, while Centene Corporation fell 8.4%, indicating varied performance among companies reporting earnings.

[object Object]
Preview
5.0
11-10Newsfilter
Celldex Appoints Teri Lawver as Chief Commercial Officer

  • New Appointment: Celldex has appointed Teri Lawver as Senior Vice President and Chief Commercial Officer, succeeding Richard Wright, who is retiring after over a decade of service.

  • Teri Lawver's Background: Ms. Lawver brings 30 years of experience in the healthcare sector, with a strong focus on immunology and inflammation, and has held significant roles at companies like Dexcom and Johnson & Johnson.

  • Company's Future Plans: Lawver's expertise is expected to be crucial as Celldex prepares for the potential launch of its drug barzolvolimab and continues to advance its pipeline of therapies for allergic and inflammatory diseases.

  • Forward-Looking Statements: The announcement includes forward-looking statements regarding the company's future performance and the risks associated with drug development and commercialization.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Celldex Therapeutics Inc (CLDX) stock price today?

The current price of CLDX is 29.6 USD — it has increased 6.44 % in the last trading day.

arrow icon

What is Celldex Therapeutics Inc (CLDX)'s business?

Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.

arrow icon

What is the price predicton of CLDX Stock?

Wall Street analysts forecast CLDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLDX is 54.67 USD with a low forecast of 21.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Celldex Therapeutics Inc (CLDX)'s revenue for the last quarter?

Celldex Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

arrow icon

What is Celldex Therapeutics Inc (CLDX)'s earnings per share (EPS) for the last quarter?

Celldex Therapeutics Inc. EPS for the last quarter amounts to -1.01 USD, increased 57.81 % YoY.

arrow icon

What changes have occurred in the market's expectations for Celldex Therapeutics Inc (CLDX)'s fundamentals?

The market is revising Downward the revenue expectations for Celldex Therapeutics, Inc. (CLDX) for FY2025, with the revenue forecasts being adjusted by -21.83% over the past three months. During the same period, the stock price has changed by 29.43%.
arrow icon

How many employees does Celldex Therapeutics Inc (CLDX). have?

Celldex Therapeutics Inc (CLDX) has 186 emplpoyees as of December 05 2025.

arrow icon

What is Celldex Therapeutics Inc (CLDX) market cap?

Today CLDX has the market capitalization of 1.97B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free